PLAU and neoplasm: A potentially clinically useful regulator of zymogen activation is also a monoclonal antibody that binds to the proenzyme of urokinase-type plasminogen activator (uPA), which is an enzyme that converts plasminogen to plasmin [61] and is involved in tumor progression and metastasis.